Daiichi Sankyo Files New Drug Application for Amoldipine Beslyte, Olmesartan Medoxomil Combination for Hypertension Treatment.
Pending approval, the combination will be indicated for the treatment of hypertension and may be used either alone or in combination with other antihypertensive agents.
In a clinical trial, the amlodipine/olmesartan combination demonstrated clinically significant mean blood pressure reductions. It utilizes two complementary mechanisms of action, calcium channel blockade and angiotensin II receptor blockade.
Benicar, Daiichi Sankyo's currently marketed ARB, is the fastest growing medication in the fastest growing class of blood pressure-lowering drugs. Norvasc is the most widely used CCB on the market.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Dec 7, 2006|
|Previous Article:||Asahi Glass Increases Fluon ETFE Fluoropolymer Production Capacity.|
|Next Article:||Toray Files New Drug Application of TRK-820 Antipruritic Agent, Treatment of Severe Pruritus in Hemodialysis Patients in Japan.|